journal article·2023-05

Piezocatalytic 2D WS2 Nanosheets for Ultrasound‐Triggered and Mitochondria‐Targeted Piezodynamic Cancer Therapy Synergized with Energy Metabolism‐Targeted Chemotherapy

Quan Truong Hoang, Kim Anh Huynh, Thuy Giang Nguyen Cao, Ji Hee Kang, Xuan Nghia Dang, Vasanthan Ravichandran, Han Chang Kang, Minjong Lee, Jong‐Eun Kim, Young Tag Ko, Tae Il Lee, Min Suk Shim

Advanced Materials· Volume 35· Issue 18
Publisher page

Abstract

Abstract Piezoelectric nanomaterials that can generate reactive oxygen species (ROS) by piezoelectric polarization under an external mechanical force have emerged as an effective platform for cancer therapy. In this study, piezoelectric 2D WS2 nanosheets are functionalized with mitochondria‐targeting triphenylphosphonium (TPP) for ultrasound (US)‐triggered, mitochondria‐targeted piezodynamic cancer therapy. In addition, a glycolysis inhibitor (FX11) that can inhibit cellular energy metabolism is loaded into TPP‐ and poly(ethylene glycol) (PEG)‐conjugated WS2 nanosheet (TPEG‐WS2) to potentiate its therapeutic efficacy. Upon US irradiation, the sono‐excited electrons and holes generated in the WS2 are efficiently separated by piezoelectric polarization, which subsequently promotes the production of ROS. FX11‐loaded TPEG‐WS2 (FX11@TPEG‐WS2) selectively accumulates in the mitochondria of human breast cancer cells. In addition, FX11@TPEG‐WS2 effectively inhibits the production of adenosine triphosphate . Thus, FX11@TPEG‐WS2 exhibits outstanding anticancer effects under US irradiation. An in vivo study using tumor‐xenograft mice demonstrates that FX11@TPEG‐WS2 effectively accumulated in the tumors. Its tumor accumulation is visualized using in vivo computed tomography . Notably, FX11@TPEG‐WS2 with US irradiation remarkably suppresses the tumor growth of mice without systemic toxicity. This study demonstrates that the combination of piezodynamic therapy and energy metabolism‐targeted chemotherapy using mitochondria‐targeting 2D WS2 is a novel strategy for the selective and effective treatment of tumors.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Extracellular vesicles in disease · MXene and MAX Phase Materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Nano‐Bioengineering Incheon National University Incheon 22012 Republic of Korea

Department of Materials Science and Engineering Gachon University Seongnam Gyeonggi‐Do 13306 Republic of Korea

College of Pharmacy Gachon University Incheon 21936 Republic of Korea

Department of Pharmacy Integrated Research Institute of Pharmaceutical Sciences and BK21 PLUS Team for Creative Leader Program for Pharmacomics‐based Future Pharmacy College of Pharmacy The Catholic University of Korea Gyeonggi‐do 14662 Republic of Korea

Department of Internal Medicine Ewha Womans University College of Medicine Seoul 07804 Republic of Korea

Department of Prosthodontics Yonsei University College of Dentistry Seoul 03722 Republic of Korea

Funding

National Research Foundation of Korea

References (67)

Show source-provided references
1. 10.1002/advs.20200122310.1002/advs.202001223 ↗
2. 10.1002/adma.20180680310.1002/adma.201806803 ↗
3. 10.1016/S1369-7021(13)70011-710.1016/S1369-7021(13)70011-7 ↗
4. 10.1002/adma.20110295810.1002/adma.201102958 ↗
5. 10.1126/science.112400510.1126/science.1124005 ↗
6. 10.1016/j.nanoen.2016.02.04610.1016/j.nanoen.2016.02.046 ↗
7. 10.1002/advs.20210086410.1002/advs.202100864 ↗
8. 10.1016/j.cej.2022.13503910.1016/j.cej.2022.135039 ↗
9. 10.1021/acsnano.1c0061610.1021/acsnano.1c00616 ↗
10. 10.1016/j.cej.2022.13638010.1016/j.cej.2022.136380 ↗
11. 10.1002/adma.20200197610.1002/adma.202001976 ↗
12. 10.1016/j.ultrasmedbio.2014.11.01910.1016/j.ultrasmedbio.2014.11.019 ↗
13. 10.1016/j.ultrasmedbio.2007.04.01810.1016/j.ultrasmedbio.2007.04.018 ↗
14. 10.1002/adma.20150242210.1002/adma.201502422 ↗
15. 10.1002/smll.20160344610.1002/smll.201603446 ↗
16. 10.1002/adma.20190233310.1002/adma.201902333 ↗
17. 10.1038/natrevmats.2017.3310.1038/natrevmats.2017.33 ↗
18. 10.1016/j.nanoen.2019.10408310.1016/j.nanoen.2019.104083 ↗
19. 10.1016/j.bioactmat.2021.04.02110.1016/j.bioactmat.2021.04.021 ↗
20. 10.1002/adma.20130525610.1002/adma.201305256 ↗
21. 10.1002/adfm.20200845210.1002/adfm.202008452 ↗
22. 10.1021/jz301243610.1021/jz3012436 ↗
23. 10.1021/acsnano.5b0339410.1021/acsnano.5b03394 ↗
24. 10.1021/acs.jpcc.5b0642810.1021/acs.jpcc.5b06428 ↗
25. 10.1002/adma.20200321410.1002/adma.202003214 ↗
26. 10.1039/C9CS00648F10.1039/C9CS00648F ↗
27. 10.1016/j.cell.2011.02.01310.1016/j.cell.2011.02.013 ↗
28. 10.1016/j.ccr.2013.02.00510.1016/j.ccr.2013.02.005 ↗
29. 10.1038/nrd414510.1038/nrd4145 ↗
30. 10.1002/cmdc.20120017610.1002/cmdc.201200176 ↗
31. 10.1158/0008-5472.CAN-03-329410.1158/0008-5472.CAN-03-3294 ↗
32. 10.1007/s10863-015-9604-110.1007/s10863-015-9604-1 ↗
33. 10.1002/adfm.20150142210.1002/adfm.201501422 ↗
34. 10.1126/science.109932010.1126/science.1099320 ↗
35. 10.1021/jacs.6b1339910.1021/jacs.6b13399 ↗
36. 10.1073/pnas.091443310710.1073/pnas.0914433107 ↗
37. 10.1158/1535-7163.MCT-08-104910.1158/1535-7163.MCT-08-1049 ↗
38. 10.1002/advs.20160016010.1002/advs.201600160 ↗
39. 10.1002/adma.20130449710.1002/adma.201304497 ↗
40. 10.1038/s41699-017-0016-410.1038/s41699-017-0016-4 ↗
41. 10.1021/acs.biomac.5b0164210.1021/acs.biomac.5b01642 ↗
42. 10.1039/C5EE03813H10.1039/C5EE03813H ↗
43. 10.1038/srep1742210.1038/srep17422 ↗
44. 10.1016/j.cej.2017.07.06410.1016/j.cej.2017.07.064 ↗
45. 10.1021/nl201874w10.1021/nl201874w ↗
46. 10.1021/ja501686w10.1021/ja501686w ↗
47. 10.1021/nn302422x10.1021/nn302422x ↗
48. 10.1016/j.addr.2015.09.01210.1016/j.addr.2015.09.012 ↗
49. 10.1039/C7NR04199C10.1039/C7NR04199C ↗
50. 10.1016/j.nanoen.2022.10717210.1016/j.nanoen.2022.107172 ↗
51. 10.1016/j.inoche.2021.10882210.1016/j.inoche.2021.108822 ↗
52. 10.1038/sdata.2015.910.1038/sdata.2015.9 ↗
53. 10.1016/j.ultsonch.2010.11.01610.1016/j.ultsonch.2010.11.016 ↗
54. 10.1021/nl501793a10.1021/nl501793a ↗
55. 10.1038/s41598-021-88395-110.1038/s41598-021-88395-1 ↗
56. 10.1126/sciadv.160006910.1126/sciadv.1600069 ↗
57. 10.1002/adts.20190000110.1002/adts.201900001 ↗
58. 10.1002/advs.20190291310.1002/advs.201902913 ↗
59. 10.1002/aenm.20200021410.1002/aenm.202000214 ↗
60. 10.1098/rsfs.2015.001910.1098/rsfs.2015.0019 ↗
61. 10.1042/BJ2008138610.1042/BJ20081386 ↗
62. 10.1016/j.canlet.2013.03.03410.1016/j.canlet.2013.03.034 ↗
63. 10.1038/s41598-019-40617-310.1038/s41598-019-40617-3 ↗
64. 10.1111/j.1742-4658.2012.08748.x10.1111/j.1742-4658.2012.08748.x ↗
65. 10.1016/j.biomaterials.2019.11940510.1016/j.biomaterials.2019.119405 ↗
66. 10.7150/thno.3718410.7150/thno.37184 ↗
67. 10.1002/smll.20190257710.1002/smll.201902577 ↗